Does rivaroxaban reduce recurrent stroke compared to aspirin in patients with ESUS and predictors of atrial fibrillation?
Rivaroxaban may reduce the risk of recurrent stroke in ESUS patients with moderate or severe left atrial enlargement, though independent confirmation is needed.
The HAVOC score, left atrial diameter, and premature atrial contraction frequency predicted subsequent clinical AF. Rivaroxaban was associated with a reduced risk of recurrent stroke among patients with ESUS and moderate or severe left atrial enlargement; however, this needs to be independently confirmed before influencing clinical practice.
Healey et al. (2019) studied this question.